Elevated serum circulating cell-free mitochondrial DNA in amyotrophic lateral sclerosis

Area of Science:

• Neuroimmunology
• Mitochondrial Biology
• Neurodegenerative Diseases

Background:

• Inflammation plays a significant role in amyotrophic lateral sclerosis (ALS).
• Circulating cell-free mitochondrial DNA (ccf-mtDNA) is implicated in immune activation and neurodegeneration.

Purpose of the Study:

• To quantify serum ccf-mtDNA levels in ALS patients.
• To explore the association between ccf-mtDNA and ALS disease characteristics.

Main Methods:

• Serum ccf-mtDNA levels were measured in 62 ALS patients and 46 healthy controls.
• Interleukin-6 (IL-6) levels were assessed in 26 ALS patients.
• Correlations between ccf-mtDNA, disease progression (ΔFS, ALSFRS-R), and IL-6 were analyzed.

Main Results:

• ALS patients exhibited significantly higher serum ccf-mtDNA levels compared to controls.
• Elevated ccf-mtDNA was most pronounced in ALS patients with superoxide dismutase 1 (SOD1) mutations.
• Serum ccf-mtDNA levels negatively correlated with ALS progression rate (ΔFS) and positively with IL-6 levels.

Conclusions:

• Increased serum ccf-mtDNA in ALS patients suggests a role in inflammatory pathways and disease pathogenesis.
• ccf-mtDNA may serve as a potential biomarker for monitoring ALS progression, especially in SOD1 mutation carriers.